ENACT Trial Information Not Available in Provided Evidence
The provided evidence does not contain information about the ENACT trial or its clinical trial phases (Phase 1,2, or 3) for amphotericin B in cryptococcal meningitis. The evidence consists primarily of treatment guidelines and clinical trials, but none specifically reference a trial called "ENACT."
What the Evidence Does Contain
The available evidence discusses several clinical trials and treatment approaches for amphotericin B in cryptococcal meningitis, but these are not identified as the ENACT trial:
Major Clinical Trials Referenced
Liposomal amphotericin B dose-comparison trial - A randomized, double-blind trial comparing conventional amphotericin B deoxycholate (0.7 mg/kg/day) versus liposomal amphotericin B at two doses (3 mg/kg/day and 6 mg/kg/day) in AIDS-associated cryptococcal meningitis 1
Ambition trial (ISRCTN72509687) - A phase 3 randomized controlled noninferiority trial conducted in five African countries comparing single-dose liposomal amphotericin B (10 mg/kg) plus flucytosine and fluconazole versus WHO-recommended amphotericin B deoxycholate regimen 2
Phase 2 short-course liposomal amphotericin B trial (ISRCTN 10248064) - Examined early fungicidal activity of three short-course, high-dose liposomal amphotericin B regimens in Tanzania and Botswana 3
Treatment Guidelines Referenced
Multiple IDSA (Infectious Diseases Society of America) practice guidelines from 2000 for cryptococcal disease management 4
CDC/NIH/HIVMA recommendations from 2004 for treating opportunistic infections 4
Recommendation for Finding ENACT Trial Information
To obtain information about the ENACT trial phases, you would need to:
- Search clinical trial registries (ClinicalTrials.gov, ISRCTN registry, EudraCT)
- Review publications specifically naming the ENACT trial
- Contact the trial investigators or sponsoring institution directly
The evidence provided does not allow me to answer your specific question about ENACT trial phases.